Clinical Trial Update: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 study evaluating Orelabrutinib plus R-CHOP in treatment-naïve patients with the MCD subtype of diffuse large B-cell lymphoma (DLBCL).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)
• R-CHOP

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: Diffuse Large B Cell Lymphoma (DLBCL) | Phase 3 | Status: UNKNOWN